Growth Metrics

Omeros (OMER) Shares Outstanding (Weighted Average) (2010 - 2026)

Omeros recorded quarterly Shares Outstanding (Weighted Average) of $71.9 million in Q1 2026, up 13.24% quarter-over-quarter from $63.5 million in Q4 2025, and up 23.87% year-over-year from $58.1 million in Q1 2025.

Omeros' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $71.9 million for Q1 2026.

  • In Q1 2026, Shares Outstanding (Weighted Average) rose 23.87% year-over-year to $71.9 million; the TTM figure through Mar 2026 stood at $71.9 million (up 23.87% YoY), while the FY2025 annual figure was $63.5 million, up 9.18% from the prior year.
  • Shares Outstanding (Weighted Average) came in at $71.9 million for Q1 2026 at Omeros, up from $63.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $71.9 million in Q1 2026 to a low of $200000.0 in Q2 2022.
  • A 5-year average of $58.0 million and a median of $62.7 million in 2022 frame the typical range for Shares Outstanding (Weighted Average).
  • On a YoY basis, Shares Outstanding (Weighted Average) climbed as much as 31262.39% in 2022 and fell as far as 99.68% in 2022.
  • Omeros' Shares Outstanding (Weighted Average) stood at $62.7 million in 2022, then grew by 0.0% to $62.7 million in 2023, then retreated by 7.28% to $58.2 million in 2024, then climbed by 9.18% to $63.5 million in 2025, then climbed by 13.24% to $71.9 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods registered $71.9 million, $63.5 million, and $66.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 177,333.76 Bn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 185,491.37 Bn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 100.00 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 55.66 Bn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 118.76 Bn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 254.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - 16.04 Bn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 104.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 132.89 Mn
10 Omeros 772.03 Mn 636.71 Mn 9.31 Mn 71.92 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 71.92 Mn
Dec 31, 2025 63.51 Mn
Sep 30, 2025 66.26 Mn
Jun 30, 2025 58.32 Mn
Mar 31, 2025 58.06 Mn
Dec 31, 2024 58.17 Mn
Sep 30, 2024 58.23 Mn
Jun 30, 2024 57.94 Mn
Mar 31, 2024 58.80 Mn
Dec 31, 2023 62.74 Mn
Sep 30, 2023 62.84 Mn
Mar 31, 2023 62.83 Mn
Dec 31, 2022 62.74 Mn
Sep 30, 2022 62.73 Mn
Jun 30, 2022 200,000.00
Mar 31, 2022 62.72 Mn
Dec 31, 2021 62.34 Mn
Sep 30, 2021 62.27 Mn
Jun 30, 2021 62.15 Mn
Mar 31, 2021 200,000.00
Dec 31, 2020 57.18 Mn
Sep 30, 2020 55.68 Mn
Jun 30, 2020 243,115.00
Mar 31, 2020 54.30 Mn
Dec 31, 2019 49.52 Mn
Sep 30, 2019 43,115.00
Jun 30, 2019 49.05 Mn
Mar 31, 2019 49.01 Mn
Dec 31, 2018 48.58 Mn
Sep 30, 2018 48.65 Mn
Jun 30, 2018 48.38 Mn
Mar 31, 2018 48.28 Mn
Dec 31, 2017 45.54 Mn
Sep 30, 2017 46.26 Mn
Jun 30, 2017 43.93 Mn
Mar 31, 2017 43.83 Mn
Dec 31, 2016 40.45 Mn
Sep 30, 2016 41.06 Mn
Jun 30, 2016 39.18 Mn
Mar 31, 2016 38.32 Mn
Dec 31, 2015 37.56 Mn
Sep 30, 2015 1.15 Mn
Jun 30, 2015 1.15 Mn
Mar 31, 2015 36.48 Mn
Dec 31, 2014 33.23 Mn
Sep 30, 2014 34.01 Mn
Jun 30, 2014 33.93 Mn
Mar 31, 2014 30.90 Mn
Dec 31, 2013 28.56 Mn
Sep 30, 2013 27.98 Mn
Jun 30, 2013 28.20 Mn
Mar 31, 2013 25.91 Mn
Dec 31, 2012 24.16 Mn
Sep 30, 2012 25.83 Mn
Jun 30, 2012 22.45 Mn
Mar 31, 2012 22.43 Mn
Dec 31, 2011 22.21 Mn
Sep 30, 2011 22.25 Mn
Jun 30, 2011 22.17 Mn
Mar 31, 2011 22.06 Mn
Dec 31, 2010 21.42 Mn
Sep 30, 2010 21.39 Mn
Jun 30, 2010 21.34 Mn